Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 18/20 | 0.81 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020658 | 1.00 | HPRT1 (0.81) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL9189420 | 1.00 | HPRT1 (0.81) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL173060 | 0.91 | HPRT1 (0.81) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL9175736 | 0.91 | HPRT1 (0.81) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL84257 | 0.91 | HPRT1 (0.81) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL16057472 | 0.89 | HPRT1 (0.68) | HPRT1 | |
| SCHEMBL17194159 | 0.88 | HPRT1 (0.70) | HPRT1PNPMEN1ALDH1A1LMNA | |
| SCHEMBL14669070 | 0.88 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL14669071 | 0.88 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL14669187 | 0.88 | HPRT1 (0.71) | HPRT1MEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220306660-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-3578563-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-09-10 | — | — | US | disclosed |
| EP-3401320-B1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS FOR USE IN TREATING HUMAN PAPILLOMA VIRUS, CERVICAL INTRAEPITHELIAL NEOPLASIA, ANAL INTRAEPITHELIAL NEOPLASIA, OR VULVAR INTRAEPITHELIAL NEOPLASIA | UNIV CALIFORNIA (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-10449207-B2 | Acyclic nucleoside phosphonate diesters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3515923-A1 | PRODRUGS OF FLUORINATED ACYCLIC NUCLEOSIDE PHOSPHONATES | Katholieke Universiteit Leuven (BE) | 2019-07-31 | — | — | EP | disclosed |
| EP-2794624-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-5733896-A | VIRICIDE FOR RETROVIRUS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-03-31 | — | — | US | disclosed |
| EP-0454427-B1 | Antiretroviral bases | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1995-12-06 | — | — | EP | disclosed |
| EP-0540707-B1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-11-15 | — | — | EP | disclosed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | disclosed |
| EP-0540707-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION. | CESKOSLOVENSKA AKADEMIE VED (CS) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992020692-A1 | DI(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | GILEAD SCIENCES, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020691-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | C^¿ESKOSLOVENSKÁ AKADEMIE VE^¿D (CS) | 1992-11-26 | — | — | WO | disclosed |
| EP-0454427-A1 | Antiretroviral bases | Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885PNP 149/4885MEN1 904/4885 |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885PNP 149/4885MEN1 904/4885 |
| US-10449207-B2 | Acyclic nucleoside phosphonate diesters | NTPCR, PNP, TYMP | HPRT1 57/4885PNP 2/4885MEN1 2016/4885 |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | HPRT1 778/4885PNP 299/4885MEN1 944/4885 |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885PNP 149/4885MEN1 904/4885 |
| US-20220306660-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885PNP 149/4885MEN1 904/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | HPRT1 327/4885PNP 64/4885MEN1 4840/4885 |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885PNP 149/4885MEN1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.